Core Viewpoint - The article highlights the rising trend of pregabalin abuse in China, particularly among youth, as a substitute for previously abused substances like dextromethorphan, raising concerns about its potential for addiction and the need for monitoring [1][2][10]. Group 1: Case Reports and Trends - Recent reports indicate a significant increase in cases of pregabalin abuse, with a notable rise in patients seeking treatment for dependency [1][2][18]. - A case study published in March 2025 documented the first reported instance of pregabalin dependency in China, where a patient escalated their dosage from 16-32 capsules daily to 80 capsules within a month [18]. - The Shandong Drug Adverse Reaction Monitoring Center reported a minor patient who switched to pregabalin after dextromethorphan was regulated, with doses reaching up to 30 capsules per use [2][18]. Group 2: Mechanism and Effects - Pregabalin is primarily used to treat neuropathic pain and anxiety disorders, but its mechanism of action, which lowers neuronal excitability, is being misused for anxiety relief and emotional escape [9][10]. - Users report initial euphoric effects, but prolonged use leads to negative side effects, including paranoia and cognitive decline, as seen in the experiences of individuals like Wang Long [8][9]. Group 3: Accessibility and Regulation - Pregabalin is easily accessible online, often without the need for a legitimate prescription, making it a popular choice among those seeking to abuse substances [16][25]. - The article discusses the potential need for stricter regulations on pregabalin, similar to those imposed on dextromethorphan, due to the increasing number of abuse cases [17][22]. Group 4: Social Dynamics and Influence - Social media and peer influence play significant roles in the spread of drug abuse, with users sharing experiences and recommendations that encourage others to try pregabalin [10][14]. - The normalization of drug use within certain social circles contributes to the ongoing cycle of addiction, as individuals seek to escape negative emotions and social pressures [26][27]. Group 5: Treatment and Prevention Challenges - The article emphasizes the challenges in addressing drug abuse, noting that many individuals do not seek help until their addiction has severely impacted their lives [26][28]. - There is a call for a multi-tiered prevention approach that includes education for at-risk populations, early intervention for those exhibiting risky behaviors, and comprehensive treatment for those already dependent [27].

Group 1 - The article highlights concerns regarding the improper fitting and sale of orthokeratology lenses for myopia correction among teenagers, emphasizing the safety risks associated with unqualified practices [1] - The provincial drug supervision administration has announced plans for thorough inspections and corrective actions against non-compliant practices in the fitting and sale of orthokeratology lenses [1] - Parents are advised to ensure that the fitting of orthokeratology lenses is conducted at qualified medical institutions with the necessary certifications to protect their children's eye health [1] Group 2 - A case is reported where a teenager overdosed on a cough medicine containing dextromethorphan, raising concerns about the regulation of such medications, especially regarding sales to minors [2] - The provincial drug administration clarified that dextromethorphan is classified as a controlled substance, with strict regulations prohibiting its sale to minors and online sales [2] - Ongoing inspections will focus on retail enterprises selling special drug formulations to ensure that minors are protected from potential drug abuse [2] Group 3 - New regulations for labeling traditional Chinese medicine pieces have been introduced, requiring clear labeling of product attributes, including expiration dates, effective from August 1, 2025 [3] - The provincial drug administration has initiated self-inspections among traditional Chinese medicine producers to comply with the new labeling requirements and ensure product quality [3] - The administration aims to address issues raised by the public and improve the regulatory framework to support the high-quality development of the pharmaceutical industry [3]